HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 41, 29831-29846, October 12, 2007

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 282/41/29831    most recent M706110200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meng, X. W. Articles by Kaufmann, S. H. Search for Related Content PubMed PubMed Citation Articles by Meng, X. W. Articles by Kaufmann, S. H. Social Bookmarking                      What's this?

MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis

A MECHANISTIC BASIS FOR SORAFENIB (BAY 43-9006)-INDUCED TRAIL SENSITIZATION^*

Xue Wei Meng¹, Sun-Hee Lee¹, Haiming Dai, David Loegering, Chunrong Yu^¶, Karen Flatten, Paula Schneider, Nga T. Dai, Shaji K. Kumar^||, B. Douglas Smith^**, Judith E. Karp^**, Alex A. Adjei^¶, and Scott H. Kaufmann^||2

From the Divisions of Oncology Research and ^¶Medical Oncology, Department of Oncology, Department of Molecular Pharmacology and Experimental Therapeutics, and ^||Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905 and ^**Adult Leukemia Program, Sidney Kimmel Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland 21287

Previous studies have suggested that Mcl-1, an antiapoptotic Bcl-2 homolog that does not exhibit appreciable affinity for the caspase 8-generated C-terminal Bid fragment (tBid), diminishes sensitivity to tumor necrosis factor--related apoptosis-inducing ligand (TRAIL). This study was performed to determine the mechanism by which Mcl-1 confers TRAIL resistance and to evaluate methods for overcoming this resistance. Affinity purification/immunoblotting assays using K562 human leukemia cells, which contain Mcl-1 and Bcl-x_L as the predominant antiapoptotic Bcl-2 homologs, demonstrated that TRAIL treatment resulted in binding of tBid to Bcl-x_L but not Mcl-1. In contrast, TRAIL caused increased binding between Mcl-1 and Bak that was diminished by treatment with the caspase 8 inhibitor N-(N-acetylisoleucylglutamylthreonyl) aspartic acid (O-methyl ester)-fluoromethyl ketone (IETD(OMe)-fmk) or the c-Jun N-terminal kinase inhibitor SP600125. In addition, TRAIL caused increased binding of Bim and Puma to Mcl-1 that was inhibited by IETD(OMe)-fmk but not SP600125. Further experiments demonstrated that down-regulation of Mcl-1 by short hairpin RNA or the kinase inhibitor sorafenib increased TRAIL-induced Bak activation and death ligand-induced apoptosis in a wide variety of neoplastic cell lines as well as clinical acute myelogenous leukemia specimens. Collectively, these observations not only suggest a model in which Mcl-1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity.

Received for publication, February 14, 2007 , and in revised form, August 10, 2007.

^* This work was supported in part by National Institutes of Health Grant R01 CA69008 (to S. H. K.), an Amgen scholar award (to S. K. K.), and a predoctoral fellowship from the Mayo Foundation for Education and Research (to S.-H. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S3.

¹ Both authors contributed equally to this work.

² To whom correspondence should be addressed: Division of Oncology Research Guggenheim 1342 C, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905. Tel.: 507-284-8950; Fax: 507-284-3906; E-mail: Kaufmann.scott{at}mayo.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. Dai, X. W. Meng, S.-H. Lee, P. A. Schneider, and S. H. Kaufmann Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis J. Biol. Chem., July 3, 2009; 284(27): 18311 - 18322. [Abstract] [Full Text] [PDF]

				J. E. Karp, K. Flatten, E. J. Feldman, J. M. Greer, D. A. Loegering, R. M. Ricklis, L. E. Morris, E. Ritchie, B. D. Smith, V. Ironside, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide Blood, May 14, 2009; 113(20): 4841 - 4852. [Abstract] [Full Text] [PDF]

				J. H. Song, K. Kandasamy, and A. S. Kraft ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis J. Biol. Chem., September 5, 2008; 283(36): 25003 - 25013. [Abstract] [Full Text] [PDF]

				S.-H. Kim, M. S. Ricci, and W. S. El-Deiry Mcl-1: A Gateway to TRAIL Sensitization Cancer Res., April 1, 2008; 68(7): 2062 - 2064. [Abstract] [Full Text] [PDF]